New hope for stomach cancer: triple therapy shows promise in early trial
Disease control
Ongoing
This study tests a combination of three treatments (anlotinib, TQB2450, and chemotherapy) as a first-line therapy for people with advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The goal is to see if this combination can shrink tumors and contr…
Phase: PHASE2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated May 18, 2026 12:11 UTC